MCL Literature Feed

This retrospective Chinese study validates POD24 (progression within 24 months) as a powerful negative prognostic marker and incorporates it into a new model to better risk-stratify relapsed patients.

In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.

Combining acalabrutinib with bendamustine-rituximab is safe and highly active, achieving a 78% complete response rate and unreached median progression-free survival at 47.6 months in treatment-naive mantle cell lymphoma.

This review outlines emerging therapeutic strategies, including non-covalent BTKis, CAR-T, and bispecifics, for managing the clinically challenging population of MCL patients relapsing after covalent BTK inhibitors.

This review summarizes how BTKi integration into frontline therapy (TRIANGLE trial) challenges the role of transplant, while CAR-T cells are established as the best option after BTKi failure.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

Brexu-cel CAR-T therapy induced a durable 15-month complete remission in a rapidly progressing, relapsed/refractory MCL patient post-BTKi, highlighting its efficacy despite manageable rare cardiovascular toxicities.

A high-risk, TP53-mutated MCL patient achieved a durable 2-year complete remission with brexucabtagene autoleucel, but developed prolonged severe cytopenias and clonal hematopoiesis, highlighting efficacy and toxicity.

This case report illustrates the efficacy of CAR-T therapy in a relapsed/refractory MCL patient who progressed after both autologous transplant and BTK inhibitor treatment, reinforcing its clinical value.

Long-term follow-up of the Philemon trial confirms durable responses for the chemotherapy-free triplet of ibrutinib, lenalidomide, and rituximab in relapsed/refractory MCL.

This review summarizes current and emerging therapies for relapsed/refractory MCL, highlighting key strategies like BTKi/BCL2i combinations, CAR-T, and bispecific antibodies for this poor-prognosis population.

This review contextualizes CAR-T therapy's established role in relapsed/refractory MCL, summarizing universal challenges such as toxicity, access, cost, and the need for effective salvage treatments post-progression.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

In relapsed/refractory MCL, the phase 3 SYMPATICO trial established ibrutinib plus venetoclax as superior to ibrutinib alone, significantly improving median progression-free survival by nearly 10 months.

Robotic-assisted bronchoscopy offers a safe, minimally invasive method for biopsying hard-to-reach aortopulmonary lymph nodes, as demonstrated in a case confirming MCL recurrence.

This review outlines management strategies for delayed complications of CAR T-cell therapy in MCL, moving beyond acute CRS and ICANS to improve long-term patient care and outcomes.

Fixed-duration glofitamab monotherapy achieves high complete response rates (78%) in heavily pretreated relapsed/refractory MCL, including post-BTKi patients, offering a potent new off-the-shelf immunotherapy.

This case report details the management of severe brexu-cel toxicities, including a rare intestinal perforation, and highlights the use of anakinra for ICANS, emphasizing complex toxicity management.

This case report describes a rare MCL relapse presenting as diabetes insipidus due to CNS involvement of the hypothalamus, highlighting an unusual manifestation of extranodal disease.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

Pirtobrutinib achieves an 81% overall response rate in MCL patients intolerant to prior covalent BTKis, offering a well-tolerated sequential option to maintain effective BTK pathway inhibition.

A rare case of MCL transdifferentiating into a clonally-related T-cell lymphoma demonstrates a novel transformation mechanism where B-cell markers are lost, complicating diagnosis at relapse.

The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.

This first-in-literature case report identifies sclerosing cholangitis as a novel, severe hepatobiliary toxicity of Tecartus CAR-T therapy in a relapsed/refractory MCL patient, expanding the known safety profile.

This case report highlights the critical role of MRI in diagnosing post-CAR-T neurotoxicity in MCL, demonstrating findings like limbic encephalitis to differentiate ICANS from other CNS pathologies.

This meta-analysis of tirabrutinib monotherapy in relapsed/refractory B-cell lymphomas, including MCL, shows a pooled 72.5% overall response rate with manageable neutropenia and skin-related toxicities.

This case report details persistent cytokine release syndrome in an MCL patient after glofitamab, highlighting a rare, severe toxicity profile requiring vigilant management beyond standard CRS protocols.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

A case of ganciclovir-resistant CMV encephalitis in a pirtobrutinib-treated MCL patient highlights a rare but severe infectious complication, urging vigilance for CNS symptoms with this non-covalent BTKi.